论文部分内容阅读
目的通过研究介孔分子筛SBA-15对奥美沙坦的组装及释放情况,考察介孔分子筛对药物的缓释机制,开发新型药物载体材料。方法以三嵌段表面活性剂P123为模板剂,正硅酸乙酯(TEOS)为硅源,按照TEOS-P123(1∶0.017)的物质的量比,使用水热合成法合成介孔分子筛SBA-15。并利用溶剂挥发法将奥美沙坦组装于SBA-15分子孔道中,利用XRD、氮吸附、红外光谱法对组装前后的分子筛进行了表征,并进一步研究了组装于分子上的筛奥美沙坦在模拟胃液及模拟肠液中的释放情况。结果 XRD图谱、氮吸附脱附曲线、红外光谱图表征均表明奥美沙坦成功组装于SBA-15孔道内。吸附到介孔分子筛上的奥美沙坦酯在模拟胃液中5 h时仅释放了30%左右,较短时间内,组装体中奥美沙坦在模拟肠液中的释放速率高于其在模拟胃液中的释放速率,随时间延长两体系释放速率逐渐接近。结论介孔分子筛SBA-15对奥美沙坦具有明显的缓释作用。
OBJECTIVE To study the assembly and release of olmesartan by mesoporous molecular sieve SBA-15 and to investigate the sustained release mechanism of mesoporous molecular sieve to develop new drug carrier material. Methods Mesoporous molecular sieves SBA were synthesized by the hydrothermal method using tri-block surfactant P123 as template and TEOS as silicon source according to the molar ratio of TEOS-P123 (1: 0.017) -15. Olisartan was assembled in SBA-15 molecular channels by solvent evaporation method. The molecular sieves before and after assembly were characterized by XRD, nitrogen adsorption and infrared spectroscopy. The effects of olmesartan Simulated gastric juice and simulated intestinal fluid release. Results XRD patterns, nitrogen adsorption and desorption curves, and IR spectra indicated that olmesartan was successfully assembled in SBA-15 cells. Olmesartan Medoxomil adsorbed on the mesoporous molecular sieve released only about 30% in simulated gastric juice for 5 h. In a short time, the release rate of olmesartan in simulated intestinal fluid was higher than that in simulated gastric fluid Release rate, with the extension of the two system release rate gradually close. Conclusion Mesoporous molecular sieve SBA-15 has obvious sustained release effect on olmesartan.